Transfer of metyrapone and its metabolite, rac-metyrapol, into breast milk.
Metyrapone, an inhibitor of corticosteroid biosynthesis, is used in the diagnosis and treatment of adrenocortical hyperfunction. The authors describe the excretion of metyrapone and its metabolite, rac-metyrapol, in milk from a lactating woman requiring metyrapone treatment (250 mg 4 times daily). At steady state, the average concentrations in milk and absolute and relative infant doses were 11 microg/L, 1.7 microg/kg/d, and 0.02%, respectively, for metyrapone, and 48.5 microg/L, 7.3 microg/kg/d, and 0.08%, respectively, for rac-metyrapol. The findings suggest that maternal metyrapone use during breastfeeding is extremely unlikely to be a significant risk for the breastfed infant.
Hotham
Neil J
NJ
Department of Pharmacy, Women's and Children's Hospital, North Adelaide, South Australia.
Ilett
Kenneth F
KF
Hackett
L Peter
LP
Morton
Mark R
MR
Muller
Peter
P
Hague
William M
WM
D000328:Adult; D019540:Area Under Curve; D001942:Breast Feeding; D002851:Chromatography, High Pressure Liquid; D003480:Cushing Syndrome / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008797:Metyrapone / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008895:Milk, Human / Q000737:chemistry* / Q000378:metabolism; D013997:Time Factors
D004791:Enzyme Inhibitors; D008797:Metyrapone